Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFRT Combined with Systemic Therapy for Oligoprogressive NSCLC
NCT07193641Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 72 weeks. Started Jun 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07193641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193641.